bioMérieux is up 2%, outperforming the trend in Paris, buoyed by favorable comments from brokers following the publication of the in vitro diagnostics group's first-half results last Friday.
Stifel reaffirmed its 'buy' recommendation and price target of €108 on the stock, even though it judged the publication to be 'mixed', with sales in line with consensus, but ROC below expectations.
The Group has a lot to look forward to over the coming months (Spotfire, Vidas kube and Vitek instruments), so we think there's room for positive surprises", says the broker.
While lowering its price target from 117 to 111 euros, Invest Securities also reiterates its 'buy' opinion on bioMérieux, judging that 'the growth reservoir seems far from exhausted' and that 'the group has the resources to be active in the M&A field'.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
BIOMÉRIEUX 
